Your Expert Speakers
Speakers
Alexey Bersenev
Lab Director
Yale School of Medicine
Day Two
Wednesday 26th October 2022
2:30 pm | Round Table Discussion – Facilitating Discussion, Debate & Collaboration Around Potency Assay Design & Implementation to Front Load for Regulatory Success
Alexey Bersenev
Assistant Professor of Clinical Lab Medicine, Facility Director, Cell Therapy Labs
Yale University, Yale-New Haven Hospital
Day Two
Wednesday 26th October 2022
9:20 am | Chair’s Opening Remarks
Andrew Weinberg
Chief Scientific Officer & PresidentCompany Details
AgonOx, Inc.
Day One
Tuesday 25th October 2022
8:50 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL
Day Two
Wednesday 26th October 2022
2:00 pm | Are Tumor-Reactive TIL Really Exhausted or Can They Be Rescued For Adoptive T cell Therapy: Clinical Implications
Charles Mooney
CEO
Biosharing Network
Day One
Tuesday 25th October 2022
8:40 am | Chair’s Opening Remarks
Daniel Powell
Assocaite Professor of Pathology & Laboratory Medicine
University of Pennsylvania
Day One
Tuesday 25th October 2022
12:30 pm | Methods for Enrichment of TIL with Autologous Tumor-Reactivity & Stem-Like Qualities
8:50 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL
Eduardo Davila
Associate Director & Professor
University of Colorado Denver
Pre-Conference Day
Monday 24th October 2022
3:00 pm | Workshop C - Optimizing Cryopreservation to Support the Development of TIL Therapies
Friedrich Graf Finckenstein
Chief Medical Officer
Iovance Biotherapeutics
Day One
Tuesday 25th October 2022
8:50 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL
Ian Hardy
R&D Reagents
Miltenyi Biotec
Day One
Tuesday 25th October 2022
10:00 am | CliniMACS Prodigy TRT System: Streamlining TIL Manufacturing
Jan Meulen
Chief Scientific Officer
Obsidian Therapeutics
Day Two
Wednesday 26th October 2022
12:30 pm | Engineering an IL2-Free, Potent & Persistent TIL With Regulated Membrane-Bound IL15
Jennifer Chain
Director, Research & Development, Chief Scientific Officer, Oklahoma Blood Institute
CytoGrowth Solutions, BioSharing Network
Day One
Tuesday 25th October 2022
12:00 pm | Pooled PBMC Feeder Cells: Benefits for Growing TIL Therapies
Karrie Wong
Director of Cell Therapy
KSQ Therapeutics, Inc
Pre-Conference Day
Monday 24th October 2022
9:00 am | Workshop A - Developing an Analytical Genotoxicity Package: From Preclinical Development Through Drug Product Release & Beyond
Liz Franks
Scientist, Cell Therapy
University of Colorado Anschutz Medical Campus
Pre-Conference Day
Monday 24th October 2022
3:00 pm | Workshop C - Optimizing Cryopreservation to Support the Development of TIL Therapies
Mark Dudley
Chief Scientific Officer
Instil Bio
Day One
Tuesday 25th October 2022
11:30 am | Developing a Novel Costimulatory Antigen Receptor With Dual CD28/ CD40 Signaling Domains to Improve Adoptive Cell Therapies
8:50 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL
Micah Benson
Chief Scientific Officer
KSQ Therapeautics
Day Two
Wednesday 26th October 2022
11:30 am | Rational Design of CRISPR/Cas9-engineered TIL Therapies
Michael Lotze
Chief Cell Therapy Officer
Nurix Therapeutics
Day One
Tuesday 25th October 2022
2:00 pm | Combining TIL with Small Molecule Inhibitors to Enhance T – Cell Expansion & Phenotypes
8:50 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL
Moran Meiron
Senior Director of Advanced Therapies
Orgenesis Inc.
Day Two
Wednesday 26th October 2022
9:30 am | Decentralized Approach to Autologous Cell Therapy Manufacturing – Advantages of Harmonized TILs Manufacturing at a Point of Care
Nicholas Restifo
Cancer immunotherapy Explorer
Lyell Immunopharma Inc.
Day One
Tuesday 25th October 2022
9:30 am | Enhancing Stemness of Polyclonal T Cells to Improve Anti-Tumor Activity
Peter Prieto
Assistant Professor & Associate Director - Program, Research, Surgical Residency Program, Oncology & Research, General Surgery
University of Rochester Medical Center
Day One
Tuesday 25th October 2022
4:00 pm | Panel Discussion: Strategies & Approaches for Ensuring Clinical Success of TIL Therapies
Sergio Quezada
Chief Scientific Officer & Co-Founder
Achilles Therapeutics Limited
Day Two
Wednesday 26th October 2022
10:00 am | Pre-Recorded: Using AI-Powered Bioinformatics & Antigen Presenting Cells to Create a Measurable & Trackable Precision TIL Product Targeting Clonal Neoantigens
Simon Turcotte
Associate professor of surgery, Université de Montréal
Université de Montréal
Day One
Tuesday 25th October 2022
4:00 pm | Panel Discussion: Strategies & Approaches for Ensuring Clinical Success of TIL Therapies
Pre-Conference Day
Monday 24th October 2022
12:00 pm | Workshop B - Cell Sorting to Manufacture TIL Products Enriched in Neoantigen-Reactive T Cells: What Are The Best Markers, Selection & Expansion Strategies?
Stephanie Woodall
Director of Quality
KSQ Therapeautics
Pre-Conference Day
Monday 24th October 2022
9:00 am | Workshop A - Developing an Analytical Genotoxicity Package: From Preclinical Development Through Drug Product Release & Beyond
Stewart Abbot
Chief Scientific Officer
Turnstone Biologics
Stewart Abbot
Chief Scientific Officer
Turnstone Biologics
Day One
Tuesday 25th October 2022
3:30 pm | Development of Selected TIL Therapies for Solid Tumors
Sylvia Lee
MD
Fred Hutchinson Cancer Research Center (FHCRC)
Day One
Tuesday 25th October 2022
4:00 pm | Panel Discussion: Strategies & Approaches for Ensuring Clinical Success of TIL Therapies
Tom Henley
CSO
Intima Bioscience
Day Two
Wednesday 26th October 2022
12:00 pm | Utilizing Multiplex CRISPR Gene Editing to Assess New Classes of Intra Cellular Immune Checkpoint Molecules for Application in TIL
Ulrik Cordes
Founder & Chief Executive Officer
Cordes Biotech A/S
Day One
Tuesday 25th October 2022
2:30 pm | Next-Gen TIL Therapy With a Broader T-Cell Repertoire – The Key to Unlocking Less Immunogenic Solid Tumor Indications
